TNSN06269A1 - SUBSTITUTED HETEROARYL AND PHENYLSULFAMOYL DERIVATIVES - Google Patents

SUBSTITUTED HETEROARYL AND PHENYLSULFAMOYL DERIVATIVES

Info

Publication number
TNSN06269A1
TNSN06269A1 TNP2006000269A TNSN06269A TNSN06269A1 TN SN06269 A1 TNSN06269 A1 TN SN06269A1 TN P2006000269 A TNP2006000269 A TN P2006000269A TN SN06269 A TNSN06269 A TN SN06269A TN SN06269 A1 TNSN06269 A1 TN SN06269A1
Authority
TN
Tunisia
Prior art keywords
les
des
cholestérol
taux
pour
Prior art date
Application number
TNP2006000269A
Other languages
French (fr)
Inventor
Ernest Seiichi Hamanaka
Marcus Eugene Kehrli Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/000526 external-priority patent/WO2005092845A1/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN06269A1 publication Critical patent/TNSN06269A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des dérivés d'hétéroaryl- et phénylsulfamoyle substitués, des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés comme agonistes du récepteur d'activateur de prolifération d'un péroxysome (PPAR). Des activateurs de PPAR alpha, des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés pour élever les taux plasmatiques de certains lipides, comprenant le cholestérol - lipoprotéine haute densité et pour abaisser les taux plasmatiques de certains autres lipides, tels que le cholestérol - LDL et les triglycérides et en conséquences pour traiter des maladies qui sont exacerbées par de faibles taux de cholestérol - HDL et/ou avec de hauts taux de cholestérol - LDL et triglycérides, telles que l'athérosclérose et les maladies cardiovasculaires, chez des mammifères, y compris les êtres humains. Les composés sont également utiles pour le traitement de l'équilibre énergétique négatif (NEB) et des maladies associées chez les ruminants.
TNP2006000269A 2004-03-10 2006-09-08 SUBSTITUTED HETEROARYL AND PHENYLSULFAMOYL DERIVATIVES TNSN06269A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55211404P 2004-03-10 2004-03-10
PCT/IB2005/000526 WO2005092845A1 (en) 2004-03-10 2005-02-28 Substituted heteroaryl- and phenylsulfamoyl compounds

Publications (1)

Publication Number Publication Date
TNSN06269A1 true TNSN06269A1 (en) 2007-12-03

Family

ID=37859499

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000269A TNSN06269A1 (en) 2004-03-10 2006-09-08 SUBSTITUTED HETEROARYL AND PHENYLSULFAMOYL DERIVATIVES

Country Status (5)

Country Link
CN (1) CN1930121A (en)
CR (1) CR8567A (en)
GT (1) GT200500042A (en)
TN (1) TNSN06269A1 (en)
ZA (1) ZA200606597B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220069A1 (en) * 2017-08-10 2022-07-14 Shanghai Jiaotong University School Of Medicine Compound used as sirt6 small-molecule allosteric activator and pharmaceutical composition thereof
CN109384694B (en) * 2017-08-10 2022-04-05 上海爱乐维生物科技有限公司 SIRT6 small-molecule agonist and application thereof

Also Published As

Publication number Publication date
ZA200606597B (en) 2007-10-31
CN1930121A (en) 2007-03-14
GT200500042A (en) 2005-10-24
CR8567A (en) 2006-10-17

Similar Documents

Publication Publication Date Title
TNSN06447A1 (en) SUBSTITUTED HETEROARYL AND PHENYLSULFAMOYL COMPOUNDS
MA27728A1 (en) ANTAGONISTS OF CGRP RECEPTORS
TNSN06368A1 (en) 3- (4-HETEROARYLCYCLOHEXYLAMINO) CYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
TNSN05158A1 (en) ASSOCIATION FOR THE TREATMENT OF ADHD
MA31151B1 (en) MAPK / ERK KINASE INHIBITORS
EA200200118A1 (en) β-CARBOLINE PHARMACEUTICAL COMPOSITIONS
DK0771197T3 (en) Use of heterocyclic compounds as dopamine D3 ligands
MA32615B1 (en) Cmet inhibitors
TNSN06038A1 (en) 3,5-DISUBSTITUTED INDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MEDIATION OR INHIBITION OF CELL PROLIFERATION
TNSN08196A1 (en) PYRAZINE DERIVATIVES
DK0544819T3 (en) Indole derivatives which inhibit leukotriene biosynthesis
TNSN06347A1 (en) MORPHOLINE DERIVATIVES
FI954944A (en) Indole derivatives as 5-HT1-like agonists used in the treatment of migraine
WO2000059486A8 (en) Use of cyp2d6 inhibitors in combination therapies
GB2408609A (en) Modular financial service instrument
GB2394712A (en) Fabrication of microstructured fibres
BR9406507A (en) Composition of fuel or lubricant polt-1-n-alkenamines and application thereof
AU2003275613A1 (en) Novel fructosyl peptide oxidase and utilization thereof
AR038207A1 (en) ORIGINALLY DISPERSABLE PHARMACEUTICAL COMPOSITION OF AGOMELATINE
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
MA26965A1 (en) ASSOCIATION OF GABA AGONISTS AND ALDOSE-REDUCTASE INHIBITORS.
TNSN07100A1 (en) DERIVATIVES OF 1, 2, 3, 4-TETRAHYDROQUINOLINE SUBSTITUTED IN POSITION 2 AND SUBSTITUTED 4-AMINO
MA31857B1 (en) SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE-AMIDES AND THERAPEUTIC USE THEREOF
NO20014756D0 (en) C (10) -heterosubstituted acetate toxans as antithrombotic agents
TNSN04225A1 (en) BENZOXAZINE DERIVATIVES AS MODULATORS OF 5-HT6 AND USES THEREOF